symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
CGTX,1.26,1.391632,40942,38192616,0,1.07-3.51,0.04,"Cognition Therapeutics, Inc.",USD,0001455365,US19243B1026,19243B102,NASDAQ Global Market,NASDAQ,Biotechnology,https://www.cogrx.com,"Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.",Ms. Lisa  Ricciardi,Healthcare,US,22,412 481 2210,2500 Westchester Avenue,Purchase,NY,10577,,0,https://financialmodelingprep.com/image-stock/CGTX.png,2021-10-08,False,False,True,False,False
